Fund Profile
Protego Ventures
Protego Ventures is an Israel-based fund investing in early-growth companies driving innovation in critical areas of defense technology, including sensors, AI/ML, and autonomous systems such as drones and unmanned aerial vehicles (UAVs). The fund focuses on companies that address the urgent need for cutting-edge defense solutions due to growing geopolitical instability.
Quick facts
HQ
Herzliya, Israel
Investor type
Venture Capital
Portfolio companies
2
Investment thesis
Focus and thesis
Protego Ventures is an Israel-based fund investing in early-growth companies driving innovation in critical areas of defense technology, including sensors, AI/ML, and autonomous systems such as drones and unmanned aerial vehicles (UAVs). The fund focuses on companies that address the urgent need for cutting-edge defense solutions due to growing geopolitical instability.
Profile links
Open the source pages
Partners and team
People behind the fund
- Lital Leshem
- Lee Moser
Portfolio companies
Selected portfolio
- XTEND
- Prisma Photonics
Fund activity
Recent activity and fund history
Recent investments
- XTEND
Fund size history
- Fund I - $150M
Investor FAQ
Frequently asked questions
What is Protego Ventures' mission?
Protego Ventures' mission is to support innovative companies and provide meaningful returns for investors while contributing to advancements in defense and security.
Where does Protego Ventures invest?
Protego Ventures invests in early-growth companies driving innovation in critical areas of defense technology, including AI & Machine Learning, Sensors, Drones, and UAVs.
What makes Protego Ventures unique?
Protego Ventures offers unparalleled access to defense priorities through exclusive partnerships, a network fueling global growth, and privileged access to the best companies in Israel's defense ecosystem.
What is the fund size of Protego Ventures?
Protego Ventures has a $150M Israeli defense fund.
Who leads Protego Ventures?
Protego Ventures is led by two women, Lital Leshem and Lee Moser.